Pappalardo A, Patti F, Restivo D A, Reggio A
Sezione Sclerosi Multipla e Malattie Demielinizzanti, Università degli Studi di Catania, Italia.
Clin Ter. 2004 Nov-Dec;155(11-12):505-28.
Multiple sclerosis is an autoimmune disease, characyerized by demylinization of white matter of Central Nervous System (CNS). Its etiology is still unknown. In the world, about 2.000.000 of people are affected by MS, with higher prevalence in North-America and North-Europe. Two are the essential features of the therapeutical management in MS: 1) immunomodulating therapy, which consists of "disease modifing drugs"; 2) symptomatic treatment. Only some patients can benefit of immunomodulating therapy, whereas symptomatic treatment can be helpfull to everbody. In the following pages the authors will review the medical options used in the diagnostic, prognostic and therapeutic management of MS.
多发性硬化症是一种自身免疫性疾病,其特征是中枢神经系统(CNS)白质的脱髓鞘。其病因仍不明。在全球,约有200万人受多发性硬化症影响,在北美和北欧患病率更高。多发性硬化症治疗管理有两个基本特征:1)免疫调节疗法,由“疾病改善药物”组成;2)对症治疗。只有部分患者能从免疫调节疗法中获益,而对症治疗对所有人可能都有帮助。在接下来的几页中,作者将回顾用于多发性硬化症诊断、预后和治疗管理的医学选择。